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The authors of the European Society of Cardiology 2016 guidelines on the diagnosis 
and treatment of acute and chronic heart failure described a new term to categorise 
patients with a resting left ventricular ejection fraction (LVEF) in the range 40-49%, 
so called heart failure with mid-range ejection fraction (HFmrEF), formerly referred to 
as “grey-area” EF in the previous iteration of the guidelines.1,2  This designation 
overlapped with the previously described heart failure with preserved ejection 
fraction (HFpEF) which had included patients with a LVEF >40% in one clinical trial 
but, more generally, patients with a LVEF >45%.3–6  Puzzlingly, the 2016 guideline 
authors continued to use the description HFpEF for patients with a LVEF ≥50%. This 
change in terminology has caused understandable confusion and should be 
replaced. 
 
So what is the problem?  The description HFpEF entered common parlance when 
used by investigators in the Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM) Programme to describe the group of patients 
enrolled in one of the three component trials.7  The word “preserved” was 
deliberately chosen to identify patients with a LVEF value that was not clearly 
“reduced” or completely “normal”. Subsequent trials have more commonly used a 
higher LVEF cut-point to identify patients with a “preserved” LVEF, usually 45% or 
above, primarily to ensure exclusion of patient with clearly reduced LVEF (given the 
variability around measurement of LVEF).3,4,8  
 
There has also been uncertainty about what constitutes a “normal” LVEF value.  The 
basis of many “reference ranges” is historical, generally lost in the mists of time.  
Fortunately, a large international collaboration has led to the pooling of individual-
person data from 43 globally representative, population-based, echocardiography 
studies, allowing for the first time the development true age-, sex- and 
racially/ethnically appropriate adult reference values for LVEF.9  Interestingly, if the 
fifth percentile is used as the lower reference value, then “normal” in an older man of 
European ancestry is 50% and that in an older European woman 51% (these values 
are higher in Asian men and women).  These normative values are in keeping with 
those advocated by the joint European Association of Cardiovascular imaging and 
the American Association of Echocardiography guidelines on chamber 
quantification.10   
 Another confusing aspect of the ESC categorization of HF relates to the 
interpretation of LVEF measured using different imaging modalities.   Normative 
values, based upon over 800 healthy volunteers, have recently been published for 
cardiac magnetic resonance (CMR) imaging, the gold standard assessment of 
cardiac volumes and LVEF.11  This study reported normative values for LVEF in 
Caucasian men and women of  ≥ 48 and 51%, respectively.  Although these results 
are similar to the normative echocardiographic results described above, there is poor 
agreement comparing LVEF by echocardiography with that of CMR, with limits of 
agreement of -18.1% to 8.3% reported.12  Added to this, two-dimensional (2D) 
echocardiography has an inter- and intra-operator variability of up to 15% and 10% 
respectively.13 As a result, a patient with “HFmrEF” could in theory be categorized as 
any of the three HF phenotypes, depending on the imaging modality used.  Indeed, 
the same patient could be assigned a diagnosis of HFpEF, HFmrEF or HFrEF within 
an hour if they were imaged by different individuals or by different modalities.  The 
high inter- and intra-operator variability of 2D echocardiography can be reduced, 
substantially, by using contrast (and there is less variability with CMR).11  This 
combination of high variability of 2D echocardiography derived EF and narrow EF 
range of HFmREF  is one of the reasons why the National Heart Foundation of 
Australia and Cardiac Society  of Australia and New Zealand have not adopted 
HFmrEF into their recently published HF guidelines, but have instead opted to keep 
a dichotomous classification of HF with HFrEF defined as an EF <50% and HFpEF 
as an EF ≥50%.14 
 
How should we use these new data to refine our categorization of heart failure by 
LVEF?  There are two options.  The first would be to revert to two phenotypes 
(HFrEF and HFpEF).  This, by definition, means that the designation “HFpEF” 
includes both patients with heart failure and a “normal” LVEF (HFnEF), as well as 
patients in the “grey area” 40-49% (for Europeans) – what in the 2016 ESC 
guidelines was defined as HFmrEF.  This is what was originally intended by the term 
HFpEF.  Although this two-category system would still be prone to potential 
misdiagnosis using 2D echocardiography as described above.   The alternative is to 
have three categories: HFrEF, HFmrEF and HFnEF, with “normal” appropriately 
defined according to age, sex and race/ethnicity.  Clearly the latter (three categories) 
is operationally more difficult to employ than the former (two categories), although 
patho-physiologically more appealing. Indeed, the discussion, debate and analyses 
which followed the introduction of the term HFmrEF has indicated that at least some 
patients in this category seem to respond favourably to treatments for patients with a 
low LVEF whereas those with a clearly “normal” LVEF do not.15–17  An arbitrary 
simplification of the 3 category solution might be to designate HFrEF as <40%, 
HFmrEF 40-54% and HFnEF as ≥55%.  
  
Regardless of the classification system used, patients with an LVEF which is neither 
very obviously reduced or normal, should have this measured as accurately as 
possible, using either contrast echocardiography or CMR, to avoid under-diagnosis 
and under-treatment of HFrEF.  Whichever of these options is preferred, it is wrong, 
at least in people of European descent, to describe patients with a LVEF ≥50% as 
having “preserved” LVEF – for men and most women ≥50% is normal. 
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